- TRADE NAMES: Akatinol; Ebixa (Lundbeck); Namenda (Forest)
- INDICATIONS: Alzheimer's disease, vascular dementia
- CLASS: Adamantane, NMDA receptor antagonist
- HALF-LIFE: 60–80 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Amantadine, Bromocriptine, Darifenacin, Dextromethorphan, Ketamine, Levodopa, Levomepromazine, Oxybutynin, Risperidone, Rotigotine, Tiotropium, Trimethoprim, Trospium, Zuclopenthixol
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of memantine in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 04/17/2025
